GFI1B: A Potential Drug Target for Cancer and Leukemia (G8328)
GFI1B: A Potential Drug Target for Cancer and Leukemia
GFI1B, also known as Growth factor independent 1B (Potential regulator of CDKN1A, translocated in CML), is a protein that plays a critical role in the regulation of cell growth and division. It is a key regulator of the CDKN1A gene, which is responsible for preventing the development of cancer. GFI1B is also involved in the regulation of the MLL-1 gene, which is involved in the development of leukemia.
GFI1B is a protein that is expressed in a wide range of tissues and cells, including the brain, spinal cord, and blood cells. It is primarily localized to the nuclei of these cells, where it functions as a negative regulator of cell growth and division. GFI1B is able to inhibit the activity of the CDKN1A gene, which encodes for the tumor suppressor protein p16INK4a. This means that when CDKN1A is active, GFI1B is able to prevent it from functioning properly.
GFI1B is also involved in the regulation of the MLL-1 gene, which encodes for the tumor suppressor protein MLL-1. MLL-1 is a critical regulator of the hematopoietic stem cell proliferation and differentiation, and is also involved in the development of leukemia. GFI1B is able to regulate the activity of MLL-1 in a similar way that it regulates the activity of CDKN1A.
GFI1B is a protein that has been shown to be involved in the development of a wide range of diseases, including cancer, leukemia, and neurodegenerative diseases. It is thought to be a potential drug target, or biomarker, for these diseases.
One way that GFI1B may be used as a drug target is by targeting the activity of CDKN1A and MLL-1. This could involve using small molecules or antibodies to inhibit the activity of GFI1B, which would in turn inhibit the regulation of CDKN1A and MLL-1. This could lead to the growth and division of cancer cells, which could be useful for treating these diseases.
Another way that GFI1B may be used as a drug target is by targeting the regulation of CDKN1A and MLL-1 in specific cell types. For example, GFI1B may be used to inhibit the activity of GFI1B in the brain, which could be useful for treating neurodegenerative diseases such as Alzheimer's disease.
In conclusion, GFI1B is a protein that plays a critical role in the regulation of cell growth and division. It is a key regulator of the CDKN1A gene, and is also involved in the regulation of the MLL-1 gene. GFI1B is thought to be a potential drug target, or biomarker, for a wide range of diseases, including cancer, leukemia, and neurodegenerative diseases. Further research is needed to fully understand the role of GFI1B in these diseases, and to develop effective treatments.
Protein Name: Growth Factor Independent 1B Transcriptional Repressor
Functions: Essential proto-oncogenic transcriptional regulator necessary for development and differentiation of erythroid and megakaryocytic lineages. Component of a RCOR-GFI-KDM1A-HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development and controls hematopoietic differentiation. Transcriptional repressor or activator depending on both promoter and cell type context; represses promoter activity of SOCS1 and SOCS3 and thus, may regulate cytokine signaling pathways. Cooperates with GATA1 to repress target gene transcription, such as the apoptosis regulator BCL2L1; GFI1B silencing in leukemic cell lines markedly increase apoptosis rate. Inhibits down-regulation of MYC and MYB as well as the cyclin-dependent kinase inhibitor CDKN1A/P21WAF1 in IL6-treated myelomonocytic cells. Represses expression of GATA3 in T-cell lymphomas and inhibits GATA1-mediated transcription; as GATA1 also mediates erythroid GFI1B transcription, both GATA1 and GFI1B participate in a feedback regulatory pathway controlling the expression of GFI1B gene in erythroid cells. Suppresses GATA1-mediated stimulation of GFI1B promoter through protein interaction. Binds to gamma-satellite DNA and to its own promoter, auto-repressing its own expression. Alters histone methylation by recruiting histone methyltransferase to target genes promoters. Plays a role in heterochromatin formation
The "GFI1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GFI1B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GFM1 | GFM2 | GFOD1 | GFOD2 | GFPT1 | GFPT2 | GFRA1 | GFRA2 | GFRA3 | GFRA4 | GFRAL | GFUS | GGA1 | GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1
